RxDoctor Payments Data

Benjamin Haden, MD

Ophthalmology · Springfield, MONPI 1952729600

Payments from drug & device makers

$2,577in general payments, 2019–2025

Across 81 payments — averaging $31.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$534
  • Alcon$514
  • Regeneron Healthcare Solutions, Inc.$428
  • Glaukos Corporation$260
  • Rxsight Inc$227
  • Genentech USA, Inc.$196
  • plus $418 from 7 others

What the payments were for

  • Food & beverage$2,48396%
  • Education$944%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,577 in reported general payments places this provider in the 55th percentile of 286 ophthalmology providers in Missouri.

See all ophthalmology providers in Missouri

Medicare billing

Part B allowed, 2024
$1,285,697
Medicare patients
699
Services billed
12,035

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine32$32,309
Prednisolone Acetate545$12,961
RocklatanNetarsudil Mesylat/Latanoprost31$12,649
Cyclosporine15$8,727
LumiganBimatoprost23$8,333
CombiganBrimonidine Tartrate/Timolol35$6,881
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat273$3,538
Latanoprost517$3,494
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol20$2,593
Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim326$2,373
Timolol Maleate151$1,202
Ketorolac Tromethamine61$1,150
Brimonidine Tartrate133$815
Dorzolamide Hcl59$795
Ofloxacin59$645

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$534$47,52390 claims
Aerie Pharmaceuticals, Inc.Rocklatan$103$12,64931 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 286 ophthalmology providers in Missouri.

Other ophthalmology in Springfield

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →